Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sedar report

<< Previous

Bullboard Posts

Next >>

Comment by Rawrasauruson Aug 17, 2021 11:41am

234 Views

Post# 33716949

RE:RE:Sedar report

I agree with you. We only need to show pain relief with no gi sides/LTE over prolonged periods of time. Even if we take a hit on how effective the relief is, it will still be incredibly useful in clinic if there are little to no risks with long term use just by lowering a patients baseline pain level.

Does anyone know the half life? I've been digging and can't seem to find it anywhere but I've heard people mention that they believe it was fully excreted after 24 hrs. That puts us at 4 hrs, which I don't believe is accurate given there proposed 1x daily dosing schedule. My guess would be 6-12 but if anyone has more concrete information, I'd love to read it.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec